Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26868745 | 0.94 | SMO (0.39) | SMOMAPK14CYP2C9KCNH2FGFR4 | |
| SCHEMBL30714644 | 0.93 | SMO (0.40) | SMOMAPK14CYP2C9KCNH2BRD4 | |
| SCHEMBL30714571 | 0.92 | MMP3 (0.40) | SMOMAPK14CYP2C9KCNH2BRD4 | |
| SCHEMBL30714606 | 0.91 | SMO (0.39) | SMOMAPK14CYP2C9KCNH2BRD4 | |
| SCHEMBL26868543 | 0.90 | SMO (0.38) | SMOMAPK14CYP2C9KCNH2BRD4 | |
| SCHEMBL31539868 | 0.86 | SMO (0.38) | SMOMAPK14CYP2C9KCNH2BRD4 | |
| SCHEMBL26868971 | 0.85 | SMO (0.40) | SMOMAPK14CYP2C9KCNH2BRD4 | |
| SCHEMBL30714638 | 0.83 | P2RY12 (0.39) | SMOMAPK14CYP2C9KCNH2BRD4 | |
| SCHEMBL26869173 | 0.82 | BRD4 (0.38) | SMOMAPK14CYP2C9BRD4CREBBP | |
| SCHEMBL30714687 | 0.82 | SMO (0.36) | SMOMAPK14CYP2C9KCNH2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | SMO 3806/4885MAPK14 2027/4885CYP2C9 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.